Bernardo Lozano, President and CEO of Avimex
Avimex’s innovative technology could solve Mexico’s vaccine challenge.
When the COVID-19 pandemic hit, Bernardo Lozano expanded the focus of his world-class veterinary pharmaceutical company, Avimex, to support the research efforts to develop a human vaccine in Mexico. This expansion fully embodies the “One Health” concept his business employs, which emphasizes that the health of animals, humans and the environment are all connected.
Bernardo’s entrepreneurial spirit and determination continue to drive significant benefit to Avimex and the medical community in Mexico. Since purchasing Avimex 35 years ago — then a small outfit treating backyard flocks — Bernardo has transformed its focus from animal treatment to disease prevention. Animal vaccines now account for more than 80% of the company’s sales. He has grown the company from just 12 to 300 employees and has invested heavily in research and development and bio-innovation. This strategy has enabled Avimex to license its patented technologies to large multinationals. It is now the leader in the poultry market in Mexico.
Bernardo’s mission goes beyond protecting animal health. In addition to the development of a human vaccine, Avimex has a thriving social responsibility program that focuses on education for low-income children. The company also supports various government initiatives that provide opportunities to young people, such as the Youth Building the Future program.
Back to the EY World Entrepreneur Of The Year™ Class of 2022